173 related articles for article (PubMed ID: 38618956)
61. Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells.
Masuda K; Ono M; Okamoto M; Morikawa W; Otsubo M; Migita T; Tsuneyoshi M; Okuda H; Shuin T; Naito S; Kuwano M
Int J Cancer; 2003 Jul; 105(6):803-10. PubMed ID: 12767066
[TBL] [Abstract][Full Text] [Related]
62. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
Brugarolas J
Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
[TBL] [Abstract][Full Text] [Related]
63. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL
Cell Oncol (Dordr); 2011 Jun; 34(3):225-34. PubMed ID: 21547579
[TBL] [Abstract][Full Text] [Related]
64. A Positive Feedback Loop between Inactive VHL-Triggered Histone Lactylation and PDGFRβ Signaling Drives Clear Cell Renal Cell Carcinoma Progression.
Yang J; Luo L; Zhao C; Li X; Wang Z; Zeng Z; Yang X; Zheng X; Jie H; Kang L; Li S; Liu S; Zhou C; Liu H
Int J Biol Sci; 2022; 18(8):3470-3483. PubMed ID: 35637958
[TBL] [Abstract][Full Text] [Related]
65. Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism.
Leisz S; Schulz K; Erb S; Oefner P; Dettmer K; Mougiakakos D; Wang E; Marincola FM; Stehle F; Seliger B
Oncotarget; 2015 May; 6(13):11395-406. PubMed ID: 25890500
[TBL] [Abstract][Full Text] [Related]
66. VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma.
Lessi F; Mazzanti CM; Tomei S; Di Cristofano C; Minervini A; Menicagli M; Apollo A; Masieri L; Collecchi P; Minervini R; Carini M; Bevilacqua G
Med Oncol; 2014 Mar; 31(3):840. PubMed ID: 24446253
[TBL] [Abstract][Full Text] [Related]
67. High VHL Expression Reverses Warburg Phenotype and Enhances Immunogenicity in Kidney Tumor Cells.
Zhu S; Ding W; Chen Y; Wang W; Xu R; Liu C; Liu X; Deng H
Genomics Proteomics Bioinformatics; 2022 Aug; 20(4):657-669. PubMed ID: 33647481
[TBL] [Abstract][Full Text] [Related]
68. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
[TBL] [Abstract][Full Text] [Related]
69. Tumor microenvironment immune subtypes for classification of novel clear cell renal cell carcinoma profiles with prognostic and therapeutic implications.
Wang Q; Hu J; Kang W; Wang J; Xiang Y; Fu M; Gao H; Huang Z
Medicine (Baltimore); 2021 Mar; 100(11):e24949. PubMed ID: 33725966
[TBL] [Abstract][Full Text] [Related]
70. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.
Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H
Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348
[TBL] [Abstract][Full Text] [Related]
71. Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance.
Razafinjatovo C; Bihr S; Mischo A; Vogl U; Schmidinger M; Moch H; Schraml P
BMC Cancer; 2016 Aug; 16():638. PubMed ID: 27530247
[TBL] [Abstract][Full Text] [Related]
72. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma.
Zhang J; Wu T; Simon J; Takada M; Saito R; Fan C; Liu XD; Jonasch E; Xie L; Chen X; Yao X; Teh BT; Tan P; Zheng X; Li M; Lawrence C; Fan J; Geng J; Liu X; Hu L; Wang J; Liao C; Hong K; Zurlo G; Parker JS; Auman JT; Perou CM; Rathmell WK; Kim WY; Kirschner MW; Kaelin WG; Baldwin AS; Zhang Q
Science; 2018 Jul; 361(6399):290-295. PubMed ID: 30026228
[TBL] [Abstract][Full Text] [Related]
73. Preliminary Study of Whole-Genome Bisulfite Sequencing and Transcriptome Sequencing in VHL Disease-Associated ccRCC.
Li L; Bao H; Xu Y; Yang W; Zhang Z; Ma K; Zhang K; Zhou J; Gong Y; Ci W; Gong K
Mol Diagn Ther; 2023 Nov; 27(6):741-752. PubMed ID: 37587253
[TBL] [Abstract][Full Text] [Related]
74. VHL promotes immune response against renal cell carcinoma via NF-κB-dependent regulation of VCAM-1.
Labrousse-Arias D; Martínez-Alonso E; Corral-Escariz M; Bienes-Martínez R; Berridy J; Serrano-Oviedo L; Conde E; García-Bermejo ML; Giménez-Bachs JM; Salinas-Sánchez AS; Sánchez-Prieto R; Yao M; Lasa M; Calzada MJ
J Cell Biol; 2017 Mar; 216(3):835-847. PubMed ID: 28235946
[TBL] [Abstract][Full Text] [Related]
75. β-catenin links von Hippel-Lindau to aurora kinase A and loss of primary cilia in renal cell carcinoma.
Dere R; Perkins AL; Bawa-Khalfe T; Jonasch D; Walker CL
J Am Soc Nephrol; 2015 Mar; 26(3):553-64. PubMed ID: 25313256
[TBL] [Abstract][Full Text] [Related]
76. TBK1 Is a Synthetic Lethal Target in Cancer with
Hu L; Xie H; Liu X; Potjewyd F; James LI; Wilkerson EM; Herring LE; Xie L; Chen X; Cabrera JC; Hong K; Liao C; Tan X; Baldwin AS; Gong K; Zhang Q
Cancer Discov; 2020 Mar; 10(3):460-475. PubMed ID: 31810986
[TBL] [Abstract][Full Text] [Related]
77. Derivative Chromosome 3 Loss from t(3;6)(q12;q14) Followed by Differential
Mizutani K; Yokoi S; Sawada S; Sakamoto I; Kameyama K; Kamei S; Hirade K; Sugiyama S; Matsunaga K; Yamada T; Kato Y; Nishihara H; Ishihara S; Deguchi T
Cancer Genomics Proteomics; 2022; 19(6):740-746. PubMed ID: 36316043
[TBL] [Abstract][Full Text] [Related]
78. von Hippel-Lindau disease-related neoplasia with an emphasis on renal manifestations.
Tekin B; Erickson LA; Gupta S
Semin Diagn Pathol; 2024 Jan; 41(1):20-27. PubMed ID: 37980175
[TBL] [Abstract][Full Text] [Related]
79. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas.
Cuevas Y; Hernández-Alcoceba R; Aragones J; Naranjo-Suárez S; Castellanos MC; Esteban MA; Martín-Puig S; Landazuri MO; del Peso L
Cancer Res; 2003 Oct; 63(20):6877-84. PubMed ID: 14583486
[TBL] [Abstract][Full Text] [Related]
80. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]